BioPulse

Clinical Trial · NCT04798339

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

← 임상시험ClinicalTrials.gov ↗
1/2상모집 중단 (진행 중)

Study Summary

This study is a multi-institution, open-label, Phase 1b/2 clinical trial evaluating the toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with lower-risk MDS who have failed prior treatment with an Erythropoietin Stimulating Agent (ESA)

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA (NCT04798339) | BioPulse